Showing 7141-7150 of 10172 results for "".
- Steve Perry Undergoes Cancer Surgeryhttps://practicaldermatology.com/news/20130611-steve_perry_undergoes_cancer_surgery/2459515/Former Journey singer Steve Perry had a cancerous mole on his right cheek removed recently. Test results found it positive for melanoma. Perry had to undergo two procedures to rid his skin of all of the cancer cells, according to his physicians, and no further treatment will be necessary.
- Avène SPF Awarded Skin Cancer Foundation Seal Of Recommendationhttps://practicaldermatology.com/news/20130611-avne_spf_awarded_skin_cancer_foundation_seal_of_recommendation/2459517/The Skin Cancer Foundation approved Avène High Protection Tinted Compact SPF 50 in both shades (Beige and Honey) to carry The Skin Cancer Foundation Active Seal of Recommendation. The coveted Seal signifies that these products have
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- Suneva Selects Quinnova to Co-promote ReFissahttps://practicaldermatology.com/news/20130610-suneva_selects_quinnova_to_co-promote_refissa/2459520/Suneva Medical, Inc. selected Quinnova Pharmaceuticals, LLC to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
- Jurlique Product Supports the Underservedhttps://practicaldermatology.com/news/20130607-jurlique_product_supports_the_underserved/2459521/The Jurlique Ideas of Beauty Fund by Jurlique and Chrysalis supports the empowerment of women to lead better lives. Through the fund, Jurlique donates to organizations around the world committed to helping women. Proceeds from every
- Renaissance and GlaxoSmithKline Transfer Nine Productshttps://practicaldermatology.com/news/20130605-renaissance_and_glaxosmithkline_transfer_nine_products/2459522/Renaissance Acquisition Holdings, LLC and GlaxoSmithKline entered into an agreement giving Renaissance the rights in the USA to manufacture, market, and sell six dermatology and three anti-viral products from GSK. The products from GSK and Stiefel, which will be marketed through Renaissance's bran
- Research Shows CLn BodyWash Effective for Children with Eczemahttps://practicaldermatology.com/news/20130603-research_shows_cln_bodywash_effective_for_children_with_eczema/2459524/Clinical study results show that TopMD Skin Care's CLn BodyWash helps ease the symptoms of eczema. The article, “A Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis,” details the results of 18 children ages 2 to 11 with moder
- Levia Targeted Phototherapy Now Part of Daavlinhttps://practicaldermatology.com/news/20130531-levia_targeted_phototherapy_now_part_of_daavlin/2459525/Daavlin has been appointed by Lerner Medical Devices to exclusively manufacture, sell, and support their Levia Targeted Home Phototherapy Device. The Levia device complements Daavlin's line of home units for the treatment of skin disorders such as psoriasis, vitiligo, and eczema. Product warranties
- New Technical Manager at Jurliquehttps://practicaldermatology.com/news/20130531-new_technical_manager_at_jurlique/2459527/Jurlique appointed Connie Lim to Technical Manager of Global Product Development. In her new role, Ms. Lim will drive innovative formula development, provide technical support, and monitor performance and key milestones in global new product development efforts. Ms. Lim comes to Jurlique with mor
- Two Melanoma Drugs Win FDA Approvalhttps://practicaldermatology.com/news/20130530-two_melanoma_drugs_win_fda_approval/2459528/The FDA approved two new drugs for metastatic or inoperable melanoma, dabrafenib (Tafinlar) and trametinib (Mekinist). Dabrafenib is an inhibitor of the BRAF gene when it carries the so-called V600E mutation. Trametinib inhibits a target known as MEK and is effective primarily against melanomas carr